Select Field
Select Ministry
23 results
Technology Introduction: After identifying the hernia type under laparoscopy, the indirect hernia, comprising 70% of inguinal hernia, is closed using the APIRS. As the procedure is proceeded at the peritoneal level where no nerve supply. Patient will not feel pain after the operation and resume to daily activities quickly. For the rest 30% of direct hernia, we use the APIRS needles to fix the mesh. This needle set can also be used to close of trocar wounds and to fix the Nuss bar. Industry Applicability: The APIRS could be widely used in many surgical fields, including 1. closure of indirect hernia (comprising 70% of inguinal hernia), 2. mesh fixation of direct hernia ( comprising 30% of inguinal hernia). 3. fixation of Nuss bar during the funnel chest surgery. 4. Closure of trocar wounds in minimally invasive surgeries. The operation is simple, effective , and easy to learn.
Future Tech | Biotechnology ＆ Medical careTechnology Introduction: The “AI Cognition Assessment & Therapy Platform” targets long assessment times, cognitive decline, and mood disturbances by deploying AI-automated cognitive assessment and personalized digital therapy modules. Combining computer vision AI and generative AI, it quickly generates a Brainmate Score and offers 15-minute interactive treatments, slowing cognitive decline, reducing depression/agitation by 20%, and cutting caregiving costs by 90%. Industry Applicability: Our team partners with Wanfang Hospital and Rai Factory Daycare to run clinical trials and set up demo site, validating 15-minute automated cognitive assessments and digital therapy that cut labor by 90% and agitation by 20%. Combining Vision AI and generative AI to quantify multidimensional movement metrics and auto-generate reports, it boosts patient engagement and family satisfaction.
Future Tech | Biotechnology ＆ Medical careTechnology Introduction: This platform introduces a non-viral gene delivery system using umbilical mesenchymal stem cells (UMSCs) engineered via electroporation to carry multiple therapeutic genes. UMSCs＇ low immunogenicity and tumor-tropic properties enable targeted delivery to solid tumors, achieving both tumor suppression and immune modulation. The approach offers high safety, scalability, and off-the-shelf potential, representing a next-generation strategy for gene and cell-based cancer therapy. Industry Applicability: This platform targets hard-to-treat solid tumors using off-the-shelf UMSCs with non-viral multi-gene delivery, offering high safety, stable expression, and tumor targeting. It supports applications in regenerative medicine, biotech, immunotherapy, and precision medicine. With scalable manufacturing, global patent coverage, and strong translational value, it offers a differentiated solution for next-generation cancer gene and cell therapy.
Future Tech | Biotechnology ＆ Medical careTechnology Introduction: This technology develops an intelligent wrist rehabilitation robot to address wrist disorder challenges. It features a magnetic series elastic actuator for non-contact force transmission and adjustable stiffness to improve safety. A self-alignment mechanism and cable-driven design enable adaptation to various users and 2-DOF control. The device quantifies joint stiffness using torque and angle data and supports multiple rehabilitation strategies aligned with stroke recovery stages. Industry Applicability: The magnetic series elastic actuator offers high safety and control stability, already applied in rehabilitation devices. Its adjustable parameters make it suitable for various industry needs. Applications include: 1. Humanoid robot hands, reducing contact force and weight; 2. Finger exoskeletons, meeting the stiffness adjustment needs of patients; 3. VR haptic devices, enhancing interaction with virtual environments. MSEA is versatile and holds great potential for industrial applications.
Future Tech | Biotechnology ＆ Medical careTechnology Introduction: This study developed innovative cancer therapy—electroactive membrane-integrated liposome nanoparticles (Au@MIL NPs). Combining electroactive liposomes and gold nanoparticles, Au@MIL NPs efficiently disrupt cancer cells＇ redox balance, inducing apoptosis without harming normal cells. Mouse and canine studies confirmed efficacy and safety, highlighting its potential as a precise, low-side-effect cancer treatment.
Future Tech | Biotechnology ＆ Medical careTechnology Introduction: Our team is developing an innovative targeted cancer therapy against methylation modifications on the tyrosine kinase epidermal growth factor receptor (EGFR). Methylation of two arginine residues in the extracellular domain of EGFR enhances ligand binding and oncogenic signaling. We have developed antibody-drug conjugates (ADCs) that specifically target methylated EGFR, aiming to establish a first-in-class therapeutic strategy for triple-negative breast cancer and other solid tumors. Industry Applicability: The RAMeE platform specifically recognizes methylated EGFR (meEGFR), a novel key antigen with tumor-promoting function. Analysis of clinical tumor samples suggests its strong prognostic and predictive value. We are actively developing antibody-drug conjugates (ADCs) and CAR-NK cell therapies targeting meEGFR. This technology shows great promise for commercialization and offers a feasible path toward first-in-class drug development and precision oncology applications targeting difficult cancers.
Future Tech | Biotechnology ＆ Medical careTechnology Introduction: Our team developed functional vegan wet fermentation (FPA) and dry additive (FPB) products using by-products to produce high surfactin content with antimicrobial activity. In broiler feed, FPA fully replaces fishmeal, and FPB replaces antibiotics, enhancing growth and economic benefits. This patented, Q1-published technology reduces carbon emissions and reuses waste, demonstrating a safe, efficient, and sustainable green circular agriculture model. Industry Applicability: This technology uses vegetarian raw materials to challenge animal-based formulas, which can reduce production costs and improve economic profits. It processes soybean hulls, bran, harvest mushroom bags, etc., which can increase the added value of feed, reduce costs and carbon emissions, and promote resource recycling. The products can be applied to other monogastric animals and also be used in agriculture, biotechnology, medicine, and food fields.
Future Tech | Biotechnology ＆ Medical careTechnology Introduction: Our team discovered that probiotic Bacillus coagulans specifically metabolizes dihydrotestosterone, treating hyperandrogenism-related diseases like androgenic alopecia, prostate disorders, and polycystic ovary syndrome (PCOS). Mouse studies confirmed significant serum dihydrotestosterone reduction and hair loss prevention. We are developing functional gut bacteria through interdisciplinary microbiota-hormone research to address excessive androgen levels regulated by enterohepatic circulation. Industry Applicability: We isolated Bacillus coagulans that specifically metabolize dihydrotestosterone, effectively reducing serum androgen equivalent. This technology creates new therapeutic pathways for hyperandrogenism conditions. Industrial applications include: (1) functional probiotic health foods for Taiwan's health market; (2) therapeutic microbial preparations; (3) postbiotic natural product development. We have completed patent applications and signed technology transfer agreements with 2 domestic companies.
Future Tech | Biotechnology ＆ Medical careTechnology Introduction: his technology introduces a world-first atrial appendage fixation device for leadless pacemakers. Delivered via transfemoral access, it anchors securely in the right atrial appendage to prevent device dislodgement and perforation. The nitinol-based structure supports device replacement and is compatible with existing systems such as Medtronic Micra AV2 and Abbott Aveir DR. It is designed to be FDA-registered as an accessory, offering a safer and scalable solution for dual-chamber leadless pacing Industry Applicability: This novel atrial appendage fixation device enables safe right atrial implantation of leadless pacemakers. Compatible with systems like Micra AV2 and Aveir DR, it addresses a critical unmet need in dual-chamber pacing. With regulatory positioning as an FDA “accessory,” it offers accelerated commercialization and strong licensing potential. The technology is well-suited for integration or spin-off development targeting high-growth cardiovascular markets.
Future Tech | Biotechnology ＆ Medical careTechnology Introduction: This technology is an integrated laparoscopic electrosurgical device with proximal active smoke evacuation, featuring the proprietary Electrocautery-Evacuation Synchronizer (EES) system. Compared to trocar-based smoke evacuation and smoke-reducing coated electrodes, it offers superior efficiency and real-time smoke removal. The device enhances surgical safety, improves ergonomic control, and is compatible with a wide range of electrosurgical and suction systems. Industry Applicability: This technology addresses smoke accumulation and hazardous exposure in minimally invasive surgery through an integrated solution featuring proximal real-time smoke evacuation and high-efficiency filtration. It effectively removes intra-abdominal smoke, enhances endoscopic visibility, and filters over 99% of VOCs and harmful particles. By reducing exposure risks for medical staff, it supports precision surgery and ESG-aligned occupational health, clinical value and global market potential.
Future Tech | Biotechnology ＆ Medical careTechnology Introduction: This study presents a lightweight (6 g), flexible, and wireless patch (9 × 5 × 0.9 cm) for non-contact cardiopulmonary monitoring. An LC resonant circuit generates a magnetic field that penetrates clothing and couples with underlying conductive tissues in the heart and lungs. Physiological motion alters impedance, shifting the resonant frequency. The patch integrates sensing and wireless modules on a flexible PCB. Signals are sampled at 12.5 Hz and transmitted to a mobile app and cloud platform. Industry Applicability: Emergency waiting areas are often overcrowded, with limited medical staff and resources. This study introduces a lightweight, flexible, non-contact patch for rapid cardiopulmonary monitoring without removing clothing. Data are wirelessly uploaded to a cloud platform for real-time physiological assessment and objective triage decisions. The system also applies to long-term care, disaster response, and other settings requiring fast screening, offering strong clinical and commercial potential.
Future Tech | Biotechnology ＆ Medical careTechnology Introduction: This technology platform integrates multi-omics and liquid biopsy data of pancreatic cancer, combined with in silico analysis and patient-derived models, to precisely decode molecular subtypes, immune microenvironment, and drug responses. It has been clinically validated in over 400 patient cases, enabling non-invasive disease monitoring and personalized treatment decision-making, with high potential for clinical translation and commercialization. Industry Applicability: This platform integrates cfDNA and EV-based liquid biopsy for tumor monitoring and treatment response, with companion diagnostic potential. Using multi-omics and AI, it builds drug sensitivity and prognosis models for personalized therapy. Gene therapies offer high specificity and low toxicity. Applied in 400+ cases, it expands to other GI cancers and smart medicine, with robust data management and cross-disciplinary collaboration, advancing commercialization and Taiwan’s biotech growth.
Future Tech | Biotechnology ＆ Medical careTechnology Introduction: This project defines "Sng" as a novel somatosensory modality distinct from pain. By integrating molecular neurobiology, clinical diagnosis, linguistic corpus studies, AI behavioral analysis, and precision therapies, the project develops dedicated diagnostic scales and multimodal interventions, improving identification and treatment of chronic sng-pain while also enhancing intercultural medical communication and advancing outcomes in global healthcare. Industry Applicability: This technology integrates clinical and fundamental research, enabling widespread adoption of the sng assessment scale across healthcare institutions and advancing personalized care and precision medicine. AI systems support both patient diagnostics and animal model evaluations, improving accuracy and accelerating therapeutic validation. In parallel, linguistic corpus analysis enhances intercultural medical communication by clarifying how pain descriptors vary across languages, thereby fostering international collaboration in biomedical practice. This dual focus—scientific rigor in neurobiology and cultural insight in linguistics—strengthens Taiwan’s competitive advantage, expanding industry-academia cooperation and setting a global benchmark in the research, diagnosis, and treatment of chronic sng-pain.
Future Tech | Biotechnology ＆ Medical careTechnology Introduction: Traumatic brain injury (TBI) is difficult to treat due to the blood-brain barrier and limited drug delivery. We developed a hydrogel-based system combining miR-6236 sponge DNA, cationic polymers, and magnetic field responsiveness. This platform protects DNA, enhances cellular uptake, and enables localized delivery. In animal models, it reduced inflammation, promoted neural repair, and improved recovery—offering a promising, targeted approach for TBI and other neurological conditions. Industry Applicability: TBI lacks effective treatments despite its global impact. We developed a conductive hydrogel-based gene delivery platform enabling targeted brain delivery and neural regeneration. This versatile system shows strong potential for TBI and other CNS disorders like stroke and Alzheimer’s, addressing critical needs in a multi-billion-dollar neuroregenerative medicine market.
Future Tech | Biotechnology ＆ Medical careTechnology Introduction: This technology is the first multimodal non-contrast MRI system for evaluating pelvic venous congestion. It integrates 3D venography and 2D flow analysis to quantify reflux and provide both visual and numeric outputs. Validated in over 800 clinical cases and cross-institutionally, it was published in the top-tier journal IJS (JCI 2nd), won Taiwan’s 2024 National Innovation Award, and holds patents in Taiwan and the U.S., with strong clinical and commercial potential. Industry Applicability: This technology is the first non-contrast MRI protocol integrating MR sequences for venous structure and flow quantification, with high clinical maturity and cross-institutional validation. It supports venous diagnostics, health screening, and pre-surgical evaluation. The prototype is deployed in hospitals, with expansion and commercialization planned, including flow analysis services and international licensing potential.
Future Tech | Biotechnology ＆ Medical careTechnology Introduction: ProDEP is the world＇s first programmable single-cell manipulation platform that integrates Taiwan’s standard CMOS process with AI-based control for precision biomedical applications. By overcoming traditional limitations in standardization and automation, it enables high-precision, label-free, and contactless cell sorting and transport. With patents filed in Taiwan, the US, and Japan, and multiple IEEE publications, ProDEP provides a concrete foundation for next-generation smart medical devices. Industry Applicability: ProDEP is a single-cell automated platform built on Taiwan’s semiconductor technology to address biomedical needs. Using proprietary chips and devices, it enables non-contact, label-free cell handling and sorting with traceable cell trajectories and replicable workflows features. It can be applied to cell therapy development, drug testing, regenerative medicine, and training. The goal is to enable decentralized cell preparation and help Taiwan export core smart medical technologies.
Future Tech | Biotechnology ＆ Medical careTechnology Introduction: Transcranial Temporal Interference Stimulation (tTIS) is a non-invasive deep brain stimulation technique that utilizes high-frequency alternating currents to generate low-frequency interference within the brain, enabling precise modulation of deep neural structures. Our team has developed a functional tTIS hardware device, completed animal studies and safety certification, and has obtained clinical trial approval. We are currently conducting rehabilitation trials in patients with dementia. Industry Applicability: The tTIS technology has strong commercialization potential, targeting patients with dementia, Parkinson’s disease, spinal cord injury, and chronic pain. It can be applied in clinical treatment and remote rehabilitation, offering a cost-effective alternative to surgery and medication. With deep targeting, high safety, and wearable design, the system is well-positioned for regulatory approval and global commercialization through medical partnerships.
Future Tech | Biotechnology ＆ Medical careTechnology Introduction: The half-maximal inhibitory concentration (IC₅₀) is a key pharmacological parameter for quantifying drug efficacy. We developed a label-free, contrast-enhanced surface plasmon resonance imaging technique to assess drug-induced cytotoxicity in cells. Compared to conventional assays such as cell proliferation kits and viability fluorescent staining, our platform yields highly consistent results. It enables accurate IC₅₀ measurement with the advantages of high throughput and label-free detection. Industry Applicability: A novel surface plasmon resonance sensing platform integrating patented nanoplasmonic chips with contrast-enhanced imaging technology offers label-free detection with high sensitivity and low cost. This technology is broadly applicable in the biomedical field, providing high-throughput and accurate evaluation of drug efficacy with strong market potential. The platform is also well-suited for applications such as molecular interaction analysis, pollutant monitoring, and food safety testing.
Future Tech | Biotechnology ＆ Medical careComing soon!
